Literature DB >> 16437904

[Enucleation-resection of pancreatic neuroendocrine tumors: 25 years of experience].

C Pasquali1, C Sperti, P Baratella, G Liessi, S Pedrazzoli.   

Abstract

From 1980 to 2004, out of 109 patients who underwent surgery for neuroendocrine pancreatic tumor, 33 had a simple tumor excision. Seventy-two percent of cases were insulinomas. Age, sex, site and size of the tumor, associated diseases, hospital stay and complications were retrospectively reviewed by the clinical records. Patients (12 males and 21 females) averaged 56.8 years, range 20-86. Mean size of the tumor was 1.7 cm and 54.5% were in the pancreatic head; 78.8% of cases had medical associated diseases. Hospital stay was 12 days (median; range, 6-81 days) and mean period of gastric suction was 4 days. Forty-eight percent had a uneventful postoperative course. Complications were divided in early (related to pancreatic surgery, related to general open surgery and medical) and late events. Complication related to pancreatic surgery were 6/33 (18%); 5 pancreatic fistulas (4 low output) and 1 acute pancreatitis, while 5/33 had a general surgery complication (2 leacking due to gastric and duodenal associated operations). Medical complications were recorded in 13 cases. Late complications occurred in 4 cases (2 incisional hernias, 1 pseudocyst and 1 keloid). No patient was re-operated for pancreatic complications; 1 was reoperated for evisceration and 1 for hyper-parathyroidism in the early post-operative period. No mortality occurred. Re-evaluation of the clinical records in order to be submitted to laparoscopic surgery excluded 17/33 cases (51%) as candidate to laparoscopic approach.

Entities:  

Mesh:

Year:  2005        PMID: 16437904

Source DB:  PubMed          Journal:  Suppl Tumori        ISSN: 2283-5423


  1 in total

1.  Risk of cancer development in patients with keloids.

Authors:  Ying-Yi Lu; Hung-Pin Tu; Chieh-Hsin Wu; Chien-Hui Hong; Kuo-Chia Yang; Hui-Ju Yang; Kee-Lung Chang; Chih-Hung Lee
Journal:  Sci Rep       Date:  2021-04-30       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.